Pharmaceutical News

RSS

Dexamethasone improves quality of life after laparoscopic gallbladder surgery

A study presented at the American Society of Anesthesiologists 2010 Annual Meeting in San Diego seems to confirm that a single, small dose of the steroid dexamethasone improves the post-surgical quality of life of patients receiving laparoscopic gallbladder surgery.

20 Oct 2010

AMP's automated IMA tube filling line receives commercial approval

Alliance Medical Products, Inc. ("AMP") announced today it has received commercial approval of its automated IMA tube filling line. The line will be put to use immediately for the commercial manufacture of a sterile ophthalmic ointment recently approved by the FDA.

20 Oct 2010

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

The U.S. Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).

20 Oct 2010

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Adamis Pharmaceuticals Corporation today announced the completion of the acquisition from Colby Pharmaceuticals of the remaining exclusive license agreements relating to two drug product candidates for the treatment of prostate cancer (PCa).

20 Oct 2010

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

Inspiration Biopharmaceuticals, Inc. announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.

20 Oct 2010

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Lotus Pharmaceuticals, Inc.a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China announced today that its wholly owned subsidiary, En Ze Jia Shi Pharmaceuticals, has been issued a patent by the State Intellectual Property Office of the People's Republic of China for controlled-release oral gliclazide. The patent covers the composition and preparation methods for the drug through 2030.

20 Oct 2010

Alexza reacquires U.S. and Canadian rights for Staccato Loxapine from BLS

Alexza Pharmaceuticals, Inc. announced today that it has reacquired the U.S. and Canadian rights for AZ-004 (Staccato® loxapine) from Biovail Laboratories International SRL, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.. AZ-004 is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.

20 Oct 2010

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

20 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

Flamel announces achievement of clinical development milestone with Merck Serono

Flamel Technologies announced today that it has achieved a clinical development milestone under the terms of its license agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to develop an extended release formulation of interferon beta-1a using the Medusa platform.

19 Oct 2010

Research calls for better environmental risk assessments of pharmaceuticals

The strategies used to assess the environmental risks posed by pharmaceuticals are not enough to protect natural microbial communities, reveals a researcher from the University of Gothenburg (Sweden) who is calling for better environmental risk assessments.

19 Oct 2010

Arcadia Biosciences receives Canadian marketing clearance for SONOVA 400 health product

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, today announced that Health Canada has granted the company clearance to sell SONOVA 400 in Canada. With the December 2009 completion of the New Dietary Ingredient (NDI) regulatory process in the United States, Arcadia is now able to make the health-maintaining oil available throughout the US and Canada.

19 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Few legitimate opioid users are getting information to keep medications safe

For some people with ongoing or chronic pain, opioids (medications such as oxycodone or hydrocodone) can make the difference between disability and the ability to function at near-normal levels. For those with acute pain, such as pain after surgery or injury, sound pain management with opioids can speed healing and recovery.

19 Oct 2010

Annals of Internal Medicine raises concerns over placebo standard

Much of medicine is based on what is considered the strongest possible evidence: The placebo-controlled trial. A paper published in the October 19 issue of Annals of Internal Medicine - entitled "What's In Placebos: Who Knows" calls into question this foundation upon which much of medicine rests, by showing that there is no standard behind the standard no standard for the placebo.

19 Oct 2010

60 Plus applauds FDA decision to remove unapproved colchicine products

James L. Martin, chairman of the 60 Plus Association, a seniors advocacy group, applauded the Food and Drug Administration's (FDA) decision to remove unapproved colchicine products from the market, and called on drug manufacturers, distributors and pharmacies to help the FDA protect patients from unapproved drugs.

19 Oct 2010

Long-term use of statins reduces colorectal cancer risk

A systematic review of the medical literature supports the hypothesis that statins, cholesterol-lowering drugs used to prevent cardiac problems, are associated with reduced risk of colon and rectal cancers.

19 Oct 2010

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

Finding a drug that can cross the blood-brain barrier is the bane of drug development for Alzheimer's disease and other neurological disorders of the brain. A new Penn study, published this week in the Journal of Neuroscience, has found and tested in an animal model of Alzheimer's disease a class of drug that is able to enter the brain, where it stabilizes degenerating neurons and improves memory and learning.

19 Oct 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

EMA Pediatric Committee adopts positive opinion for CTI's Pixuvri for lymphoid malignancies, solid tumors

Cell Therapeutics, Inc. ("CTI") announced today that the Pediatric Committee (the "PDCO") of the European Medicines Agency ("EMA") has adopted an opinion agreeing to CTI's Pixuvri® (pixantrone dimaleate) Pediatric Investigation Plan ("PIP") for the treatment of lymphoid malignancies and solid tumors in children between ages of 6 months and 18 years.

19 Oct 2010

Pharmaceutical News

Dexamethasone improves quality of life after laparoscopic gallbladder surgery

AMP's automated IMA tube filling line receives commercial approval

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Alexza reacquires U.S. and Canadian rights for Staccato Loxapine from BLS

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Flamel announces achievement of clinical development milestone with Merck Serono

Research calls for better environmental risk assessments of pharmaceuticals

Arcadia Biosciences receives Canadian marketing clearance for SONOVA 400 health product

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Few legitimate opioid users are getting information to keep medications safe

Annals of Internal Medicine raises concerns over placebo standard

60 Plus applauds FDA decision to remove unapproved colchicine products

Long-term use of statins reduces colorectal cancer risk

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

EMA Pediatric Committee adopts positive opinion for CTI's Pixuvri for lymphoid malignancies, solid tumors

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News